GlassScriptPhysician profile
Keisha Ellis
NPI 1508318494
$2,513.54
in general payments reported to CMS, 2019-2025
25 companies · $92.83 in 2025
The $92.83 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $424 · 2022: $567 · 2023: $1,059 · 2024: $371 · 2025: $92.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,506 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,506.07 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $426.32 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $333.11 | 2021-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $196.55 | 2021-2023 | Mounjaro |
| Amgen INC. | $158.33 | 2021-2023 | Repatha, Otezla |
| Astellas Pharma US INC | $152.01 | 2022-2024 | Veozah |
| Glaxosmithkline, LLC. | $151.55 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Neurocrine Biosciences, INC. | $140.81 | 2022-2023 | Ingrezza |
| Mylan Specialty L.P. | $136.90 | 2021-2022 | |
| Alkermes, INC. | $127.65 | 2023-2024 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $119.11 | 2023-2024 | Xarelto |
| Novo Nordisk INC | $118.80 | 2022-2025 | Ozempic |
| Xeris Pharmaceuticals, INC. | $100.09 | 2023 | Gvoke Hypopen |
| Pfizer INC. | $55.41 | 2021 | |
| Exact Sciences Corporation | $54.86 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $42.27 | 2023 | Freestyle Libre 3 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $33.32 | 2022-2023 | |
| Dexcom, INC. | $33.14 | 2023-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.76 | 2023 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $19.07 | 2023 | Austedo |
| Phathom Pharmaceuticals, INC. | $17.95 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.55 | 2023 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Optinose US, INC. | $15.09 | 2021 | |
| Medtronic, INC. | $13.95 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.83 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keisha Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.